Date: 2013-04-15
Type of information: R&D agreement
Compound: biomarkers for an undisclosed AstraZeneca cancer drug
Company: AstraZeneca (UK) Oxford Cancer Biomarkers (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: Oxford Cancer Biomarkers (OCB), a UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has announced an agreement with AstraZeneca for biomarker discovery, with the potential for further collaboration on validation and development of resulting biomarkers. OCB will work with an undisclosed AstraZeneca cancer drug to discover biomarkers that have the potential to predict responders and non-responders to the drug. Under the agreement, AstraZeneca has been granted an option to license biomarkers from the programme. Oxford Cancer Biomarkers uses its proprietary platform CancerNav® to rapidly generate predictive biomarkers for cancer drugs. It has successfully proven its platform through from biomarker discovery to clinical validation. This spin-out of the University of Oxford was founded in January 2012 by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space.
Financial terms:
Latest news:
